We focus AML with mutations of the Nucleophosmin gene (NPM1) and show evidence to suggest that wild-type NPM1 has an inhibitory influence on BRD4 that is relieved upon NPM1c mutation and ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial in patients with relapsed/refractory ...

KOMET-001 trial met its primary endpoint for ziftomenib in R/R NPM1-mutant AML, with statistically significant CR and CRh rates. Kura plans to submit an NDA for ziftomenib in Q2 2025 and initiate ...

Recent research has shown a correlation between high NPM1 mutations and VISTA expression, particularly in AML. As mutated NPM1 (mNPM1) drives leukemogenesis through menin and the efficacy of menin ...